Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

Shenouda, Andre; Douglas, Stephen A.; Ohlstein, Eliot H.; Giaid, Adel

doi:10.1177/002215540205000702

Cited by 103 publications

(66 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More detailed studies have demonstrated that both UII and UT-R are co-expressed in cardiovascular, renal and endocrine tissues (5,23). Recently, UII and UT-R have been identified in some tumor tissues including adrenal tumor (17,18), renal carcinoma (19), and pheochromocytoma (20). In addition, the expression of UII and UT-R has also been found in some tumor cell lines, such as glioblastoma cell line T98G, neuroblastoma cell line IMR32, choriocarcinoma cell line BeWo, adrenocortical carcinoma cell line SW-13, colorectal carcinoma cell line DLD-1, and cervical carcinoma cell line HeLa (16).…”

Section: Discussionmentioning

confidence: 99%

“…Takahashi et al (16) showed that UII and UT-R are expressed in glioblastoma cell line T98G, neuroblastoma cell line IMR32, choriocarcinoma cell line BeWo, adrenocortical carcinoma cell line SW-13, colorectal carcinoma cell line DLD-1, and cervical carcinoma cell line HeLa. UII and UT-R mRNA are also expressed in adrenal tumor (17,18), renal carcinoma (19), and pheochromocytoma (20,21). Furthermore, SW-13 cells has been demonstrated to secrete UII (16).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo

Zheng¹

2010

Oncol Rep

View full text Add to dashboard Cite

Abstract. Urotensin II (UII), originally identified from fish urophysis, is a potent vasoactive peptide and an endogenous ligand for an orphan G protein-coupled receptor GPR14, now named as urotensin II receptor (UT-R). In this study, we investigated the mRNA and protein expressions of UII and its receptor (UT-R) in human lung adenocarcinoma A549 cells, and the effect of exogenous UII on the proliferation of A549 cells in vitro and in vivo. Reverse transcription-polymerase chain reaction (RT-PCR) and Western blot analysis showed that both mRNAs and proteins of UII and UT-R were obviously expressed in human lung adenocarcinoma A549 cells. Immunohistochemical analysis showed that UII peptide was mainly expressed in the cytoplasm, and UT-R protein was expressed on the cytomembrane and also in the cytoplasm. 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) analysis demonstrated that treatment with different concentrations of human UII (10 -9 , 10 -8 , 10 -7 and 10 -6 M) for 48 h significantly increased the number of A549 cells. The effect of UII at the concentration of 10 -7 M on the proliferation of A549 cells is most pronounced. Nude mice bearing human lung adenocarcinoma A549 cells treated with UII showed a significant increase in tumor volume and tumor weight compared with control group. These findings suggest that UII may contribute to the pathogenesis of human lung adenocarcinoma as an autocrine/paracrine growth stimulating factor.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo

Zheng¹

2010

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…The parent compound pre-pro-UTN is highly expressed in the kidney, and UTN is abundantly represented in endothelial and smooth muscle cells of renal vessels, 38 as well as in tubular cells, and it is excreted in the urine at concentrations substantially higher than the plasma UTN concentration. 39 The kidney synthesizes relevant amounts of UTN, and together with the lung and the liver actively secretes UTN into the systemic circulation.…”

Section: Urotensin In Renal Diseases and In Esrdmentioning

confidence: 99%

Urotensin II and Cardiomyopathy in End-Stage Renal Disease

et al. 2008

View full text Add to dashboard Cite

Abstract-Circulating urotensin (UTN) is increased in patients with heart failure and in patients with renal diseases, and UTN antagonism is currently considered as a potential treatment for these conditions. Contrary to this contention, studies in end-stage renal disease suggest that, perhaps because of interference with sympathetic and NO systems, UTN may be cardioprotective. (UTN) is a cyclic undecapeptide that is widely distributed in several organ systems, including the vascular system and the heart. 1 UTN is a quite strong inotrope in isolated myocardial tissues like human right atrial trabeculae 2 and rat left ventricular (LV) papillary muscles, 3 but in vivo it reduces cardiac performance when administered on a chronic basis in the rat 4 and causes a marked cardiodepressant effect in acute experiments in primates 5,6 concomitant with a decrease in blood pressure. Because UTN promotes myocardial cell hypertrophy in vitro and activates fibrogenesis, 7,8 high gene expression of this peptide at myocardial level 9 and high circulating UTN in patients with heart failure 10 -13 have initially been considered as potentially noxious in these patients. However, recent observations in a chronic volume overload model in the rat 14 indicate that subcutaneous administration of UTN on a chronic basis may help to preserve myocardial contractility in this model. These observations go along with findings in the same model showing that bolus UTN injections exert favorable, NOdependent, renal hemodynamic effects. 15 On the other hand, UTN is reduced in patients with acute coronary syndromes, 16 and low UTN predicts adverse clinical outcomes and death in patients after myocardial infarction. 17 Overall it remains largely undefined whether UTN has a role in LV disorders in humans.End-stage renal disease (ESRD) represents an intriguing model to explore the role of UTN in cardiovascular (CV) diseases in humans because cardiomyopathy is pervasive in this condition 18 and because UTN attains high plasma levels in ESRD. 19,20 In previous studies in this population we found that UTN is inversely, rather than directly, related to CV stress hormones like norepinephrine and neuropeptide Y 20 and to the endogenous inhibitor of NO synthesis, asymmetrical dimethylarginine (ADMA). 21 UTN is a potent NOdependent vasodilator in pulmonary and mesenteric circulation in humans, 22 and we hypothesized that these links may

show abstract

“…Urotensin-II-like immunoreactivity was present in the human urine [145]. In the kidney, urotensin-II was expressed in the epithelial cells of tubules and ducts and in the endothelial cells of renal capillaries [146]. Urotensin-II secreted by renal tubular cells into urine may account for urotensin-II-like immunoreactivity in urine.…”

Section: Urotensin-iimentioning

confidence: 97%

Translational Medicine in Fish-derived Peptides: From Fish Endocrinology to Human Physiology and Diseases

Takahashi

2004

Endocr J

View full text Add to dashboard Cite

Abstract. Recent studies have revealed the importance of fish-derived peptide hormones to human endocrinology. These peptides include melanin-concentrating hormone (MCH), urocortins (human urotensin-I), and urotensin-II. MCH, a hypothalamic peptide, is a potent stimulator on appetite. Urocortins, e.g. urocortin 1 and urocortin 3 (stresscopin), are endogenous ligands for the corticotropin-releasing factor (CRF) receptors, particularly CRF type 2 receptor, that mediates a vasodilator action, a positive inotropic action and a central appetite-inhibiting action. These actions mediated by CRF type 2 receptor may ameliorate the stress response. Human urotensin-II is a potent vasoconstrictor peptide, while it acts as a vasodilator on some arteries. Human urotensin-II is expressed in various types of cells and tissues, including cardiovascular tissues, as well as many types of tumor cells. Thus, these fish-derived peptides appear to play important roles in human physiology, such as appetite regulation, stress response and cardiovascular regulation, and also in diseases, for example, obesity, cardiovascular diseases and tumors. Development of antagonists/agonists against the receptors for these peptides may open new strategies for the treatment of various diseases, including obesity-related diseases, hypertension, heart failure and malignant tumors. IN the last century, a large number of peptide hormones were discovered. Some of the novel peptides are produced and secreted by classically non-endocrine organs, such as brain, heart and vascular vessels [1], while some were originally discovered in non-mammalian species including fishes. The peptides produced by classically non-endocrine organs include hypothalamic hormones and various neuropeptides secreted by neurons [2-5], atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) by heart [6] and endothelins by vascular endothelium [7]. Some peptides appear to be ubiquitously expressed. For example, adrenomedullin, a vasodilator peptide discovered from pheochromocytoma tissue, is produced and secreted by various types of normal cells [1,8,9,10], such as fibroblasts [10], macrophages [10,11], glial cells [12] and retinal pigment epithelial cells [13,14], and by various tumor cells [1,[15][16][17][18][19]. Endothelin-1 is also ubiquitously expressed like adrenomedullin although it was originally isolated from aortic endothelial cells [7, 20, 21]. Thus, a large number of studies on hormones now aim not only at classical endocrine organs, but also at nonendocrine organs, such as cardiovascular organs.Another important aspect of the recent advances in peptide endocrinology is recognition of the importance of fish-derived hormones in human physiology and diseases. In this review, I will discuss three bioactive peptides: melanin-concentrating hormone (MCH) [22], urotensin-I [23, 24] and urotensin-II [25, 26]. These three peptides were originally discovered in fishes, and are now recognized to have very important physiological roles in mammals including human. Furt...

show abstract

Localization of Urotensin-II Immunoreactivity in Normal Human Kidneys and Renal Carcinoma

Cited by 103 publications

References 25 publications

Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo

Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo

Urotensin II and Cardiomyopathy in End-Stage Renal Disease

Translational Medicine in Fish-derived Peptides: From Fish Endocrinology to Human Physiology and Diseases

Contact Info

Product

Resources

About